Beijing Cygenta Biotech Co., Ltd. (hereinafter referred to as \"Cygenta\") is headquartered in Beijing and operates a state-of-the-art CGT cGMP facility spanning over 8,000 square meters. Our facility complies with FDA, EMA, and NMPA standards, positioning us as a leading Contract Development and Manufacturing Organization (CDMO) for gene and cell therapies.
At Cygenta, we provide comprehensive production services for plasmids, viral vectors, and cell products, supporting clients from research-grade to commercial-grade manufacturing. As of now, our commitment to excellence has enabled us to successfully support 14 Investigational New Drug (IND) applications.We are dedicated to becoming the premier partner for gene and cell therapy companies, offering unparalleled expertise and infrastructure to accelerate the development and commercialization of life-changing therapies.
Cygenta operates a total of 18 GMP production lines, including 2 independent production lines for the plasmid platform, which feature full unidirectional flow design to achieve rapid high-density fermentation processes ranging from 3 L to 200 L, with yields reaching up to gram-level per liter. The viral platform is equipped with 3 independent viral production lines, featuring a unidirectional airflow system with negative pressure and a 100% fresh air system throughout the process. It is capable of producing viral vectors with flexible scale-up from 3 L to 200 L. Additionally, the platform is equipped with 2 cell banking production lines. The cell platform operates in B+A and C+A environments, comprising 5 independent zones with a total of 11 production lines，providing process development and manufacturing services for both autologous and allogeneic cell therapies. Additionally, the quality control platform offers over 80 analytical testing methods, supporting clients with services such as analytical method development, validation, sample release testing, raw material and packaging component testing, as well as environmental monitoring.
